Free tool
FAERS Monitor: Siliq
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761032 or its brand name (Siliq, Brodalumab). Reports on generic versions are filed under their own applications.
Reports
2,061
Serious
1,808
88% of reports
Hospitalization
583
Death reported
145
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- psoriasis504
- drug ineffective240
- arthralgia195
- intentional product use issue180
- psoriatic arthropathy177
- fatigue174
- product dose omission issue145
- disease recurrence139
- therapy interrupted139
- headache131
- off label use128
- inappropriate schedule of product administration123
- diarrhoea94
- pain in extremity91
- therapy cessation88
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2013 | 1 |
| 2015 | 3 |
| 2016 | 7 |
| 2017 | 8 |
| 2018 | 118 |
| 2019 | 208 |
| 2020 | 186 |
| 2021 | 238 |
| 2022 | 341 |
| 2023 | 244 |
| 2024 | 254 |
| 2025 | 289 |
| 2026 | 164 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,098 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| psoriatic arthropathySignal | 177 | 44.7 | 38.8 | 7,499 |
| psoriasisSignal | 504 | 39.5 | 36.6 | 18,934 |
| disease recurrenceSignal | 139 | 29.9 | 25.5 | 3,851 |
| intentional product use issueSignal | 180 | 21.0 | 18.3 | 3,418 |
| therapy interruptedSignal | 139 | 19.9 | 16.9 | 2,478 |
| therapy cessationSignal | 88 | 17.5 | 14.3 | 1,356 |
| inappropriate schedule of product administrationSignal | 123 | 7.0 | 5.9 | 628 |
| product dose omission issueSignal | 145 | 5.0 | 4.3 | 471 |
| arthralgiaSignal | 195 | 4.8 | 4.2 | 592 |
| pain in extremitySignal | 91 | 3.2 | 2.6 | 133 |
| fatigueSignal | 174 | 2.3 | 2.0 | 129 |
| headacheSignal | 131 | 2.1 | 1.8 | 80 |
| drug ineffective | 240 | 1.9 | 1.7 | 101 |
| off label use | 128 | 1.5 | 1.3 | 21 |
| diarrhoea | 94 | 1.5 | 1.2 | 15 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.